Where possible, we intended to use intention-to-treat (ITT) data for the primary efficacy analyses.
The data for the primary oligo, with the highest signal, are positioned at the top for each locus.
Data for the primary endpoint was analyzed via chi-squared analyses; the secondary outcome measures were analyzed with a 2-tailed Repeated Measures analysis of variance (ANOVA), chi-squared, and/or independent or dependent t-tests, as appropriate.
Missing data for the primary endpoint were treated by multiple imputations, using a regression-switching approach (chained equation with m = 20 imputations obtained with the R statistical software version 3.03).
We subjected any imputation of missing data for the primary outcomes to sensitivity analyses; any substantial difference in the imputed ITT analyses compared to available data analyses was incorporated in the interpretation of the study findings and the discussion.
The outcome was different depending on the method used to collect data for the primary outcome.
MK provided microarray data for the primary tumours.
The data for the primary outcome measure, 6MWT, are presented in Figure 2.
As we detected considerable skew in continuous outcomes, we log transformed data for the primary analysis.
We found that NJR data for the primary procedure had nearly perfect completion.
No sub-group analyses were planned for the ITT data for the primary outcome.
